Evotec SE CSO Dohrmann to Resign JPMorgan Files Routine Disclosure

Evotec SE (NASDAQ:EVO) has announced that Dr. Cord Dohrmann, its Chief Scientific Officer, will step down on September 30, 2026. Dohrmann, who has led the company's induced pluripotent stem cell (iPSC) and omics efforts for 16 years, will leave as Evotec begins the search for his successor.

Separately, JPMorgan Chase filed a routine German major-holdings notice on September 24, 2026, disclosing that it had crossed a WpHG threshold for Evotec SE. The filing did not provide specific details about the stake but is a standard ownership disclosure required under German regulations.